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Objektif – Untuk mengkaji impak pelalian Haemophilus influenza b (Hib) ke atas jumlah 
kemasukan pesakit untuk pneumonia dan meningitis di Hospital Universiti Sains Malaysia 
dari tahun 2000 sehingga tahun 2017. 
Tatacara – Kajian retrospektif berdasarkan kod ICD-10 diagnosis yang direkodkan oleh Unit 
Rekod Perubatan Hospital USM daripada ringkasan pelepasan (discaj) pesakit. Pesakit yang 
dimasukkan di dalam kajian ini adalah yang berumur lingkungan usia 3 sehingga 60 bulan 
semasa dimasukkan untuk penyakit pneumonia and meningitis. Poisson regression digunakan 
untuk menentukan sama ada wujudnya kaitan antara jumlah kemasukan pesakit sebelum dan 
selepas imunisasi Hib dilaksanakan dan berapa lama pesakit ditahan di dalam wad untuk 
menerima rawatan sebelum dibenarkan dibenarkan pulang. 
Keputusan – analisa menunjukkan bahawa kemasukan untuk pneumonia (RR = 3.5, 95% CI: 
1.3, 13.6) dan jumlah hari berada di dalam wad (RR = 2.7, 95%CI: 1.2, 7.2) menunjukkan 
peningkatan yang ketara seiring dengan bermulanya imunisasi Hib. Walaubagaimanapun, 
semua model menunjukkan poor goodness-of-fit. 
Kesimpulan - berdasarkan analisis data, kita tidak boleh membuat kesimpulan bahawa 
imunisasi Hib adalah mempengaruhi jumlah kemasukan pesakit untuk pneumonia dan 
meningitis, dan juga jumlah hari berada di dalam wad. Terdapat banyak data yang hilang 
dalam kajian ini memandangkan ini merupakan kajian retrospektif. Lebih banyak kajian 







Objective – To study the impact of implementation of Haemophilus influenzae b (Hib) 
vaccination on the total number of hospital admission for pneumonia and meningitis in 
Hospital Universiti Sains Malaysia from year 2000 up to 2017. 
Methods – retrospective study based on diagnosis recorded by Medical Records Unit 
Hospital USM from the patients’ discharge summaries. Patients included in this study are 
those within age of 3 to 60 months during admission and when the diagnosis was made and 
admitted for pneumonia and meningitis. Poisson regression was used to determine the 
association between number of admission before and after immunization. 
Results – Analyses showed that number of admission for pneumonia (RR = 3.5, 95% CI: 1.3, 
13.6) and lengths of stay in days (RR = 2.7, 95% CI: 1.2, 7.2) significantly increased with the 
starting of Hib immunization. However, all models had poor goodness-of-fit (predicted count 
did not fit the data). 
Conclusions – Based on the analyses of the data, we cannot correlate between the 
implementation of Hib vaccination with current incidence of pneumonia and meningitis as 
there are many other factors that influence both the illness. In addition, there were many 
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Introduction: Haemophilus influenzae is one of the commonest pathogen causing 
pneumonia and meningitis. There are 6 serotypes of Haemophilus influenza, and serotype b 
(Hib) is the most virulent. The introduction of routine vaccination has led to substantial 
declines in the incidence of Hib disease. Haemophilus influenzae vaccine has been introduced 
into the immunization program in Malaysia since 2002. However, published national data 
about impact of Haemophilus influenza vaccine on cases of pneumonia and meningitis is still 
lacking.  This study mainly aims to look at the impact of implementation of Haemophilus 
influenzae vaccination to the number of cases admitted for pneumonia and meningitis in 
Paediatric wards in Hospital USM 
Objective: To study the impact of implementation of Haemophilus influenzae b (Hib) 
vaccination on the total number of hospital admission for pneumonia and meningitis in 
Hospital Universiti Sains Malaysia from year 2000 up to 2017. 
Methods: retrospective study based on diagnosis recorded by Medical Records Unit Hospital 
USM from the patients’ discharge summaries. Patients included in this study are those within 
age of 3 to 60 months during admission and when the diagnosis was made and admitted for 
pneumonia and meningitis. Poisson regression was used to determine the association between 
number of admission before and after immunization. 
Results: Analyses showed that number of admission for pneumonia (RR = 3.5, 95% CI: 1.3, 
13.6) and lengths of stay in days (RR = 2.7, 95% CI: 1.2, 7.2) significantly increased with the 
starting of Hib immunization. However, all models had poor goodness-of-fit (predicted count 
did not fit the data). 
Conclusions: Based on the analyses of the data, we cannot correlate between the 
implementation of Hib vaccination with current incidence of pneumonia and meningitis as 
there are many other factors that influence both the illness. In addition, there were many 
missing data as this is a retrospective study. Further studies are warranted. 
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Haemophilus influenzae is an infectious bacterium cause of meningitis, pneumonia, 
epiglottitis and other severe infectious diseases (such as septic arthritis, cellulitis, purulent 
pericarditis and bacteremia). Both capsulated (types a, b, c, d, e, or f) and noncapsulated 
Haemophilus influenzae can cause invasive disease especially among children under five years 
of age and immunosuppressed patients (Domenico et al., 2017). Without proper vaccination 
plans, capsulated Haemophilus influenzae type b (Hib) has unquestionably the highest incidence. 
The World Health Organization (WHO) recommends that all countries introduce Hib 
conjugate vaccine in to their routine infant immunization programs (Salvador et al., 2012). Hib 
vaccines are commonly given as a three-dose primary series at the same time as diphtheria-
tetanus-pertussis (DTP) vaccination, and several combination vaccines are available. Hib 
conjugate vaccine has been shown to be highly effective in preventing invasive Hib 
disease after a three-dose primary series. 
Several studies found the Hib conjugate vaccines to have a clear value in reducing 
meningitis incidence worldwide. Local influences including type of Hib vaccine, prevalence of 
human immunodeficiency virus (HIV) infection and vaccine coverage may be responsible for 






Surveillance systems in resource-poor settings also demonstrated Hib vaccine 
effectiveness by documenting vaccine effectiveness against purulent meningitis as well as 
declines over time in this outcome. Studies in Rwanda, Uganda, and Indonesia all showed that 
the Hib vaccine prevented approximately 50% of purulent meningitis cases. Asian countries had 
low documented incidences which presented particular difficulties with using surveillance data 
to estimate vaccine impact. Past studies of Hib in Asia demonstrated varied disease incidence 
rates, with the great majority of earlier surveillance-based studies finding low rates. 
In addition to meningitis, Hib causes a substantial proportion of paediatric bacterial 
pneumonia. However, most Hib pneumonia is non-bacteremic making it difficult to evaluate 
vaccine impact using data based on microbiologically confirmed cases no matter how good the 
surveillance system is. 
Previous studies suggested that Hib conjugated vaccine showed marked impact on the 
incidence of Hib diseases (William et al., 1993). In the United States (US), a study done showed 
that the vaccine preventing an estimated 10,000 to 16,000 cases of Hib disease in 1991. The age-
specific incidence of Hib disease among children less than 5 years old decreased by 71% (from 
37 per 100,000 persons in 1989 to 11 per 100,000 persons in 1991). The surveillance data 
showed that Haemophilus influenzae meningitis incidence decreased by 82% between 1985 and 
1991. 
Study in The Gambia, which is the first country in Africa to introduce conjugate Hib 
conjugated vaccine, also showed an effective disease control up to 14 years after introduction. 





Almost similar finding was also noted by a study done in Italy which looked on the 
impact of Hib conjugate vaccination on hospitalization for invasive disease in children fifteen 
years after its introduction. A significant decline of hospitalization rates was observed among 
children 1-4 years over the study period. 
 
1.2 PNEUMONIA 
Pneumonia is one of the commonest causes of admission of the patients especially in 
Paediatric Wards. It is frequently but not always caused by infection. The infection may be 
bacterial, viral, fungal, or parasitic.  
The WHO guidelines define pneumonia as an acute disease episode with cough or 
difficult breathing combined with fast breathing with age specific cut-off values for 
increased respiratory rate (Taneli et al., 2008). Pneumonia often starts with symptoms of upper 
respiratory tract infection followed by fever, chills and cyanosis. Children who presented with 
lower chest wall in-drawing are classified as severe pneumonia and will be referred for 
evaluation and possible in-patient care.  
Pneumonia caused substantial morbidity and mortality in all age groups. In the USA, 
pneumonia and influenza combined are the greatest infectious case of death. Pneumonia 
accounts for 3-18% of all childhood hospital admissions (Carlos et al., 2007). Community 
acquired pneumonia hospitalization causes an important health and cost burden to the country. 
One study shows that the total median direct medical cost of bacterial-acquired-pneumonia-





money could be saved if we able to prevent children from having severe pneumonia 
subsequently requiring hospital admission with simple way of providing adequate immunization. 
 
1.2.1 Etiology 
Over the past century, findings of pneumonia etiology studies in children have swung 
from detection of only bacteria to a preponderance of viruses (Daniel et al., 2017). Streptococcus 
pneumoniae was first identified in 1881 from samples of human saliva. Early access to 
antibiotics presented a difficulty for research on pneumonia etiology as prior treatment with 
antibiotics is associated with a 30% reduction in blood culture positivity in children with 
pneumonia.  The history of pneumonia etiology studies over the last century also shows several 
trends: from the use of highly specific tests on specimens from the lung itself to highly sensitive 
tests on samples of body fluids distant from the lung; from detection of single pathogens to 
detection of multiple pathogens; and from an exclusive focus on bacteria to enhanced detection 
of viruses. 
The most frequently detected bacterial agents for pneumonia were Klebsiella pneumoniae 
(5.4%), Streptococcus pneumoniae (5.2%), Escherichia coli (5.2%), Staphylococcus aureus 
(3.9%), Haemophilus influenza (3.6%) and Haemophilus parainfluenzae (3.3%) (2c). The most 
frequently detected viruses were human rhinovirus (20.3%, in just 2 studies), respiratory 
syncytial virus (RSV, 17.3%), human bocavirus (9.9%), parainfluenza virus (5.8%), human 
metapneumovirus (3.9%) and influenza (3.5%). Mycoplasma pneumoniae and Chlamydophila 
pneumoniae were identified in 9.5% and 2.9%, respectively, of children less than 5 year of age 





1.2.2 Epidemiology  
Approximately 120 – 156 million cases of acute lower respiratory infections occur 
globally, with approximately 1.4 million resulting in death (Rodrigo et al., 2016). Of these, 
pneumonia kills an estimated 1 million children under the age of 5 every year and accounts for 
15% of deaths in children less than 5 years of age, with 90 – 95% of these deaths occurring in the 
developing world. The majority of pneumonia episodes in children less than 5 years of age occur 
in just 15 countries, with South Asia and Sub-Saharan Africa collectively enduring the largest 
burden of more than half the worldwide total cases of pneumonia in children. Risk factors for 
community-acquired pneumonia (CAP) include age (less than 1 year), malnutrition, prematurity, 
immunosuppression, overcrowding, passive tobacco exposure, indoor fuel exposure, inadequate 
housing and the winter season. The burden of disease has been worsened by the human 
immunodeficiency virus (HIV) epidemic. Other co-existing illnesses, like malaria and diarrhea, 
are also important contributing factors to the increased CAP burden of disease in African and 
South Asian settings. 
 
1.2.3 Pathophysiology  
Pneumonia is an infectious process resulting from the invasion and overgrowth of 
microorganism in the lung parenchyma, breaking down defenses and provoking intra-alveolar 
exudates. The development of pneumonia requires that the pathogen reach the alveoli and that 
host defenses are overwhelmed by microorganism virulence or by the inoculum’s size. Intrusion 
of bacteria into the lower respiratory tract usually is the result of aspiration of organism from the 
upper respiratory tract. Underlying disease, loss of mechanical respiratory defenses with the use 





normal flora of the upper respiratory tract. Nasal, oropharynx, biofilm and respiratory tract 
colonization have been related to the risk for pneumonia, especially in “late-onset” pneumonia. 
Aspiration of normal oropharynx flora in a comatose patient and during intubation seems to be 
the pathogenesis of “early-onset” pneumonia. 
 
1.2.4 Clinical manifestation 
The clinical presentation of bacterial pneumonias varies (Justina, 2018). Sudden onset of 
symptoms and rapid illness progression are associated with bacterial pneumonias. Chest pain, 
dyspnea, hemoptysis, decrease exercise tolerance, and abdominal pain from pleuritis are also 
highly indicative of pulmonary process. 
The presence of cough, particularly cough productive of sputum, is the most consistent 
presenting symptom. Nonspecific symptoms such as fever, rigors and malaise are common. 
Other nonspecific symptoms that may be seen with pneumonia include myalgia, headache, 
abdominal pain, nausea, vomiting, diarrhea, anorexia and weight loss, and altered sensorium. 
Physical examination findings may vary, depending on the type of organism, severity of 
infection, coexisting host factors, and the presence of complications. Signs of bacterial 
pneumonia may include the following: 
 Hyperthermia (fever, typically > 38°C) or hypothermia (< 35°C) 
 Tachypnea 
 Use of accessory respiratory muscles 





 Central cyanosis 
 Altered mental status 
Physical findings may include the following: 
 Adventitious breath sounds, such as rales / crackles, rhonchi and wheezes 
 Decreased intensity of breath sounds 
 Egophony  
 Whispering pectoriloquy 
 Dullness to percussion 
 Tracheal deviation 
 Lymphadenopathy  
 Pleural friction rub 
 
1.2.5 Diagnosis and investigation 
The following investigations are useful not only for diagnostic purposes but also for 
classifying illness severity: 
 Blood studies 
o Full Blood Count with differential  
 Leukocytosis with a left shift may be observed in any bacterial 
infection 
 Leucopenia may be an ominous clinical sign of impending sepsis 





 An elevated International Normalized Ratio (INR) has been 
associated with more severe illness. This finding may herald the 
development of disseminated intravascular coagulation 
o Blood cultures 
 Should be obtained before the administration of antibiotics 
 When blood cultures are positive, they correlate well with the 
microbiologic agent causing the pneumonia. Their yield may be 
higher in patients with more severe pneumonia / infection 
 Unfortunately, blood cultures show poor sensitivity in pneumonia; 
findings are positive in approximately 40% of cases 
 Sputum evaluation 
o Sputum Gram stain and culture should be performed before initiating 
antibiotic therapy. A single predominant microbe should be noted at Gram 
staining. Mixed flora may be observed with anaerobic infections. 
o However, often, patients cannot produce an adequate specimen. Many 
specimens produced are so contaminated by oral materials that the results 
of stains and cultures are unreliable 
 Chest radiography 
o Considered the standard method for diagnosing the presence of 
pneumonia, that is, the presence of an infiltrate is required for the 
diagnosis 
o However, the accuracy of plain chest radiography for detecting pneumonia 





o In H influenza pneumonia, pleural effusion is present in an approximately 
half of infected individuals. 
 
1.2.6 Treatment  
 Respiratory support 
o For patients with mild shortness of breath, only supplemental oxygen with 
a nasal cannula may be required for ventilator support 
o Ventilator support becomes necessary when supplemental oxygen is not 
sufficient or when the patient cannot maintain the increased work of 
breathing 
o Moderate dyspnea requires high oxygen concentrations, such as those 
provided by Venti-mask or partial rebreathing face mask 
o Patients in respiratory failure may require endotracheal intubation and 
ventilation 
o An alternative to intubation for refractory hypoxemia may be use of 
continuous positive airway pressure (CPAP) 
o Bilevel positive airway pressure (BIPAP) may be employed as a means of 
noninvasive ventilation in patients with hypercarbia 
 Fluid resuscitation 
o Many individuals with pneumonia also have volume depletion 
o Patients with hypotension and/or tachycardia may benefit from an 






 Empiric antibiotic therapy 
o Empiric therapy for the hospitalized patient should be initially broad and 
cover the likely causative organisms 
o Maximum time from door to antibiotics administration should be within 
four hour or less. Failure to abide by these time parameters may be 
associated with poor outcome 
o The goals of pharmacotherapy for bacteria pneumonia are to eradicate the 
infection, reduce morbidity, and prevent complications 
o With appropriate antibiotic therapy, improvement in the clinical 
manifestations of pneumonia should be observed in 48 – 72 hours 
o Antibiotics should not be changed within the first 72 hours unless marked 
clinical deterioration occurs or the causative micro-organism is identified 
with some certainty 
 Supportive measures 
o Analgesia and antipyretics 
o Chest physiotherapy 
o Intravenous fluid (or diuretics) if indicated 
o Monitoring (pulse oximetry with or without cardiac monitoring 
o Oxygen supplementation 
o Positioning of patient to minimize aspiration risk 
o Respiratory therapy, including treatment with bronchodilators if indicated 
o Suctioning and bronchial hygiene 





o Systemic support – proper hydration, nutrition, early mobilization to 
create a positive host milieu to fight infection and speed recovery 
 
1.2.7 Complication and prognosis 
Potential complications of bacterial pneumonia include the following: 
 Destruction and fibrosis / organization of lung parenchyma with scarring 
 Bronchiectasis  
 Necrotizing pneumonia 
 Frank cavitation 
 Empyema  
 Pulmonary abscess 
 Respiratory failure 
 Acute respiratory distress syndrome 
 Ventilator dependence 
 Superinfection  
 Meningitis  
 Death  
 
1.3 MENINGITIS 
Meningitis is a clinical syndrome characterized by inflammation of the meninges. 





of bacterial meningitis consists of fever, headache and neck stiffness. Other symptoms can 
include nausea, vomiting, photophobia, sleepiness, confusion, irritability, delirium and coma. 
Over the years, significant advances have been made in developing approaches to 
management of meningitis. Although admission for meningitis is not as common as pneumonia, 
prompt and accurate diagnosis and adequate treatment of bacterial meningitis in children is still a 
major challenge. Until now, bacterial meningitis is still an important cause of childhood 
mortality. Those who survive are at high risk of developing neurological disability.   
 
1.3.1 Etiology 
Causes of meningitis include bacteria, viruses, fungi and parasites. There are seven 
bacterial types known to cause meningitis: Escherichia coli, Haemophilus influenzae, Neisseria 
meningitidis, Streptococcus pneumoniae, group B Streptococcus agalactiae, Staphylococcus 
aureus, and Listeria monocytogenes (Oordt-Speets et al., 2018).   
 
1.3.2 Epidemiology  
 The incidence of meningitis varies according to the specific etiologic agent, as well as in 
conjunction with a nation’s medical resources (Rodrigo, 2017). The incidence is presumed to be 
higher in developing countries because of less access to preventive services, such as vaccination. 






Meningitis affects people of all races. In the United States, black people have a higher 
reported rate of meningitis than white people and Hispanic people. 
 With almost 4100 cases and 500 deaths occurring annually in the United States, bacterial 
meningitis continues to be a significant source of morbidity and mortality. The annual incidence 
in the United States is 1.33 cases per 100,000 population. The reported attack rate for bacterial 
meningitis is 3.3 male cases per 100,000 population, compared with 2.6 female cases per 
100,000 population. 
Meningococcal meningitis is endemic in parts of Africa, India, and other developing 
areas. Periodic epidemics occur in the so-called sub-Saharan “meningitis belt,” as well as among 
religious pilgrims traveling to Saudi Arabia for the Hajj. In parts of Africa, widespread 
epidemics of meningococcal meningitis occur regularly. In 1996, the biggest wave of 
meningococcal meningitis outbreaks ever recorded arose in West Africa. An estimated 250,000 
cases and 25,000 deaths occurred in Niger, Nigeria, Burkina Faso, Chad, and Mali. 
N meningitidis causes approximately 4 cases per 100,000 children aged 1-23 months. The 
risk of secondary meningitis is 1% for family contacts and 0.1% for daycare contacts. The rate of 
meningitis caused by S pneumoniae is 6.5 cases per 100,000 children aged 1-23 months. 
Previously, Hib, N meningitidis, and S pneumoniae accounted for more than 80% of cases 
of bacterial meningitis. Since the late 20th century, however, the epidemiology of bacterial 
meningitis has been substantially changed by multiple developments. 
The overall incidence of bacterial meningitis in the US declined from 2.0 to 1.38 cases 





use of the Hib vaccination, which decreased the incidence of H influenzae meningitis by more 
than 90%. Routine Hib vaccination has nearly eliminating this pathogen as a cause of meningitis 
in many developed countries. 
 
BACTERIA 1978 - 1981 1986 1995 1998 - 2007 
Haemophilus 
influenza 
48% 45% 7% 6.7% 
Listeria 
monocytogenes 
2% 3% 8% 3.4% 
Neisseria 
meningitidis 
20% 14% 25% 13.9% 
Streptococcus 
agalactiae 
3% 6% 12% 18.1% 
Streptococcus 
pneumoniae 
13% 18% 47% 58% 
Table 1.1 Changing Epidemiology of Acute Bacterial Meningitis in United States 
H influenzae meningitis primarily affects infants younger than 2 years. S agalactiae 
meningitis occurs principally during the first 12 weeks of life. Among the bacterial agents that 





1.3.3 Pathophysiology  
 Most cases of meningitis are caused by an infectious agent that has colonized or 
established a localized infection elsewhere in the host. Potential sites of colonization or infection 
include the skin, the nasopharynx, the respiratory tract, the gastrointestinal (GI) tract, and the 
genitourinary tract. The organism invades the submucosa at these sites by circumventing host 
defenses (e.g., physical barriers, local immunity, and phagocytes or macrophages). 
An infectious agent (i.e., a bacterium, virus, fungus, or parasite) can gain access to the 
central nervous system (CNS) and cause meningeal disease via any of the 3 following major 
pathways: 
1. Invasion of the bloodstream (ie, bacteremia, viremia, fungemia, or parasitemia) and 
subsequent hematogenous seeding of the CNS 
2. A retrograde neuronal (eg, olfactory and peripheral nerves) pathway (eg, Naegleria 
fowleri or Gnathostoma spinigerum) 
3. Direct contiguous spread (eg, sinusitis, otitis media, congenital malformations, trauma, or 
direct inoculation during intracranial manipulation) 
Invasion of the bloodstream and subsequent seeding is the most common mode of spread for 
most agents. This pathway is characteristic of meningococcal, cryptococcal, syphilitic, and 
pneumococcal meningitis. 
Rarely, meningitis arises from invasion via septic thrombi or osteomyelitic erosion from 
infected contiguous structures. Meningeal seeding may also occur with a direct bacterial 





transmitted vertically, involving pathogens that have colonized the maternal intestinal or genital 
tract, or horizontally, from nursery personnel or caregivers at home. 
Local extension from contiguous extracerebral infection (eg, otitis media, mastoiditis, or 
sinusitis) is a common cause. Possible pathways for the migration of pathogens from the middle 
ear to the meninges include the following: 
1. The bloodstream 
2. Preformed tissue planes (eg, posterior fossa) 
3. Temporal bone fractures 
4. The oval or round window membranes of the labyrinths 
The brain is naturally protected from the body’s immune system by the barrier that the 
meninges create between the bloodstream and the brain. Normally, this protection is an 
advantage because the barrier prevents the immune system from attacking the brain. However, in 
meningitis, the blood-brain barrier can become disrupted; once bacteria or other organisms have 
found their way to the brain, they are somewhat isolated from the immune system and can 
spread. 
When the body tries to fight the infection, the problem can worsen; blood vessels become 
leaky and allow fluid, white blood cells (WBC) and other infection-fighting particles to enter the 
meninges and brain. This process, in turn, causes brain swelling and can eventually result in 
decreasing blood flow to parts of the brain, worsening the symptoms of infection. 
Depending on the severity of bacterial meningitis, the inflammatory process may remain 





the underlying parenchyma remains intact. However, in more severe forms of bacterial 
meningitis, the pial barrier is breached, and the underlying parenchyma is invaded by the 
inflammatory process. Thus, bacterial meningitis may lead to widespread cortical destruction, 
particularly when left untreated. 
Replicating bacteria, increasing numbers of inflammatory cells, cytokine-induced disruptions 
in membrane transport, and increased vascular and membrane permeability perpetuate the 
infectious process in bacterial meningitis. These processes account for the characteristic changes 
in CSF cell count, pH, lactate, protein, and glucose in patients with this disease. 
Exudates extend throughout the CSF, particularly to the basal cisterns, resulting in the 
following: 
1. Damage to cranial nerves (eg, cranial nerve VIII, with resultant hearing loss) 
2. Obliteration of cerebrospinal fluid (CSF) pathways (causing obstructive hydrocephalus) 
3. Induction of vasculitis and thrombophlebitis (causing local brain ischemia) 
 
1.3.4 Clinical manifestation 
 The younger the child, the less likely he or she is to exhibit the classic symptoms of 
fever, headache, and meningeal signs (Martha, 2017). A child younger than three months may 
have very nonspecific symptoms, including hyperthermia or hypothermia, change in sleeping or 
eating habits, irritability or lethargy, vomiting, high-pitched cry, or seizures. After the age of 





with fever, vomiting, irritability, lethargy, or any change in behavior. After the age of two to 
three years, children may complain of headache, stiff neck, and photophobia. 
The clinical course may be brief and fulminant with rapid progression of symptoms or 
may follow a more gradual course with several days of upper respiratory infection progressing to 
more severe symptoms. 
Physical examination findings vary widely, depending on the infecting organism and the 
patient’s age. The younger the child is, the less specific the symptoms. As the child grows older, 
the physical examination becomes more reliable. 
Kernig and Brudzinski signs are helpful indicators when present, but they may be absent 
(along with nuchal rigidity) in very young, debilitated, or malnourished infants. Skin findings 
range from a nonspecific blanching, erythematous, maculopapular rash to a petechial or purpuric 
rash, most characteristic of meningococcal meningitis. 
Patients may also have other foci of infection. Presenting symptoms may point toward 
those foci, causing unnecessary delay in diagnosis of bacterial meningitis. 
Approximately 15% of patients have focal neurologic signs upon diagnosis. The presence 
of focal neurologic signs predicts a complicated hospital course and significant long-term 
sequelae. 
Generalized or focal seizures are observed in as many as 33% of patients. Seizures that 
occur during the first three days of illness usually have little prognostic significance. However, 
prolonged or difficult-to-control seizures, especially when observed beyond the fourth hospital 





In later stages of the disease, a few patients develop focal CNS symptoms and other 
systemic signs (eg, fever) indicating a significant collection of fluid in the subdural space. 
Incidence of subdural effusion is independent of the bacterial organism causing meningitis. 
Approximately 6% of affected infants and children show signs of disseminated intravascular 
coagulation (DIC) and endotoxic shock. These signs are indicative of a poor prognosis. 
 
1.3.5 Diagnosis and investigation 
Bacterial meningitis must be the first and foremost consideration in the differential 
diagnosis of patients with headache, neck stiffness, fever, and altered mental status. Acute 
bacterial meningitis is a medical emergency, and delays in instituting effective antimicrobial 
therapy result in increased morbidity and mortality. 
A firm diagnosis is usually made when bacteria are isolated from the cerebrospinal fluid 
(CSF) and evidence of meningeal inflammation is demonstrated by increased pleocytosis, 
elevated protein level, and low glucose level in the CSF. Timely collection and processing of 
CSF and isolation of an organism allows optimization of choice of antimicrobial agent and 
duration of therapy. CSF chemistries and cytology vary, depending on the age of the patient.  
A lumbar puncture (LP) may be contraindicated in some of the following conditions: 
unstable patients with hypotension or respiratory distress who may not be able to tolerate the 
procedure, brain abscess, brain tumors or other cause of raised intracranial pressure, and 





The Bacterial Meningitis Score, a clinical decision rule developed by Nigrovic et al, has 
shown high accuracy and usability and continues to be evaluated with respect to its effectiveness 
as an aid to identify those children with CSF pleocytosis who are at low risk for bacterial 
meningitis. The components of the score include the following: 
 Positive CSF Gram stain 
 CSF absolute neutrophil count of 1000/µL or higher 
 CSF protein level of 80 mg/dL or higher 
 Peripheral blood absolute neutrophil count of 10,000/µL or higher 
 History of seizure before or at the time of presentation 
Perform total and differential cell counts, chemistries (ie, glucose and protein), Gram 
stains, and cultures on all CSF specimens. In a setting of antibiotic pretreatment, rapid bacterial 
antigen testing may be considered. Note that patients with both fulminant disease and poor 
immune response may not show cytologic or chemical changes in CSF. In about 2-3% of 
bacterial meningitis cases, bacterial cultures may be positive even when the Gram stain is 
negative and the cell counts and glucose and protein levels are normal. 
White blood cell (WBC) counts higher than 1000/µL are usually caused by bacterial 
infections. Counts of 500-1000/µL may be bacterial or viral and call for further evaluation. 
Lower counts are usually associated with viral infections. 
The CSF protein concentration is usually elevated in bacterial meningitis (greater than 50 
mg/dL), but it is also elevated by a traumatic lumbar puncture. The CSF glucose concentration is 
usually reduced in bacterial meningitis. A normal CSF glucose level should be higher than two 





bacterial meningitis. In patients with very early disease, however, CSF protein and glucose 
values may be within the reference range. 
Several tests based on the principle of agglutination are available for the detection of 
bacterial antigens in body fluids. Bacterial antigen detection can be carried out in samples of 
CSF, blood, and urine. A negative result, however, does not rule out bacterial infection. Antigen 
detection tests are most helpful in patients with partially treated meningitis in whom bacteria 
may not grow from CSF but antigens persist in body fluids. 
Many children receive antibiotics before definitive diagnosis is made. As a rule, a few 
doses of oral antimicrobial agents, or even a single injection of an antibiotic, do not significantly 
alter CSF findings, including bacterial cultures, especially in patients with Hib disease. Oral 
antibiotics have never convincingly been shown to render patients with bacterial meningitis CSF 
culture–negative. 
In cases where antibiotic administration leads to CSF sterilization, polymerase chain 
reaction (PCR) testing may have a role to play in identifying the pathogen. PCR testing is able to 
identify the pathogen quickly and accurately and does not require a large number of organisms; 
however, it does require further validation in this setting. 
Nigrovic et al. (2018) found that Gram stain results (WBC count and absolute neutrophil 
count) in CSF were not affected by pretreatment with antibiotics; however, the rates of positive 
CSF culture and blood culture were lower with antibiotic pretreatment. After pretreatment with 






A concern regarding LP is that the lowering of CSF pressure from withdrawal of CSF 
could precipitate herniation of the brain. Herniation can sometimes occur in acute bacterial 
meningitis and other CNS infections as the consequence of severe cerebral edema or acute 
hydrocephalus. Clinically, this is manifested by an altered state of consciousness, abnormalities 
in pupil reflexes, and decerebrate or decorticate posturing. The incidence of herniation after LP, 
even in patients with papilledema, is approximately 1%. 
 A screening computed tomography (CT) scan of the head may be performed before LP to 
determine the risk of herniation. The decision to obtain a brain CT scan before LP should not 
delay the institution of antibiotic therapy; such delay can increase mortality. It should be also 
noted that herniation can occur in patients with bacterial meningitis who have a normal brain CT 
scan. The most reliable clinical signs that indicate the risk of herniation include deteriorating 
level of consciousness, brainstem signs, and a very recent seizure. 
 Computed tomography (CT) of the head and magnetic resonance imaging (MRI) of the 
brain generally do not aid in the diagnosis of meningitis. Some patients may show meningeal 
enhancement, but its absence does not rule out the condition. Neuroimaging may yield normal 
results or demonstrate small ventricles, effacement of sulci, and contrast enhancement over 
convexities. Late findings include venous infarction and communicating hydrocephalus. Brain 
abscess, sinus or mastoid infection, skull fracture, and congenital anomalies must be ruled out. 
Other laboratory tests, which may include blood cultures, are needed to complement the 
CSF culture. These bacterial cultures are used for identification of the offending bacteria and 
occasionally its serogroup, as well as for determination of the organism’s susceptibility to 





 Full blood count (FBC) with differential 
 Blood cultures 
 Coagulation studies 
 Serum glucose 
 Electrolytes 
Measurement of the serum glucose level close to the time of CSF collection is helpful for 
interpreting CSF glucose levels and assessing the likelihood of meningitis. 
Some data suggest that procalcitonin may be a useful biomarker for distinguishing 
bacterial meningitis from aseptic meningitis. Its use may enhance the sensitivity of the Bacterial 
Meningitis Score. In a retrospective analysis of admitted patients with meningitis, Dubos et al 
found procalcitonin at a level of 0.5 ng/mL to have a sensitivity of 99% and a specificity of 83% 
for differentiating bacterial from aseptic meningitis. 
 
1.3.6 Treatment  
 Management of acute bacterial meningitis in infants and older children involves both 
supportive measures and appropriate antimicrobial therapy.  
Closely monitor patients’ fluid and electrolyte status. Check vital signs and neurologic 
status, and ensure that an accurate record of intake and output is maintained. By prescribing the 
correct type and volume of fluid, the risk of brain edema can be minimized. The child should 
receive sufficient amounts of fluid to maintain systolic blood pressure at around 80 mm Hg, 





avoid syndrome of inappropriate antidiuretic hormone secretion (SIADH), it is equally important 
to avoid underhydration of the patient and the risk of decreased cerebral perfusion. 
 Bacterial meningitis (including Meningococcal meningitis, Haemophilus influenzae 
meningitis, and Staphylococcal meningitis) is a neurologic emergency that is associated with 
significant morbidity and mortality. Initiation of empiric antibacterial therapy is therefore 
essential for better outcome. The choice of agents is usually based on the known predisposing 
factors, initial CSF Gram stain results, or both. Once the pathogen has been identified and 
antimicrobial susceptibilities determined, the antibiotics may be modified for optimal targeted 
treatment. All antibiotics should be administered intravenous (IV) to achieve adequate serum and 
CSF levels. An intraosseous route is acceptable if venous access is not an option. 
 Primary treatment is with either Cefotaxime (50 mg/kg IV every 6 hours, up to 12 g/day) 
or Ceftriaxone (50 mg/kg every 12 hours, up to 4 g/day). Treatment with Dexamethasone (0.4 
mg/kg IV every 12 hours for 2 days or 0.15 mg/kg IV every 6 hours for 4 days) should be 
strongly considered, starting 15-20 minutes before the first dose of antibiotics. Experimental 
studies have revealed a correlation between outcome and the severity of the inflammatory 
process in the subarachnoid space. In animal models of bacterial meningitis, the use of 
dexamethasone has been associated with decreased inflammation, reduced cerebral edema and 
intracranial pressure (ICP), and lesser degrees of brain damage. Subsequent controlled, double-
blind clinical trials demonstrated the beneficial effects of adjunctive dexamethasone in infants 
and children with Hib meningitis. The incidence of neurologic and audiologic sequelae was 
significantly decreased on follow-up examination; clinical benefit was greatest for overall 
hearing impairment. 
